Form 4 for IOVA IOVANCE BIOTHERAPEUTICS, INC.
Accepted 2025-06-06 00:00:00 ET · period of report 2025-06-05 · accession 0001104659-25-057310 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-06 | 2025-06-05 | IOVA | Kirby Daniel Gordon | Chief Commercial Off | P - Purchase | $1.84 | +30.0K | 30.0K | New | +$55.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-05 | P | A | 30,000 | $1.84 | 30,000 | D | — | — | (F1) Shares were acquired in the open market during a permitted trading window in accordance with the Issuer's Insider Trading Policy. A copy of the Insider Trading Policy is filed as Exhibit 19.1 to the Issuer's Annual Report on Form 10-K for the year ended December 31, 2024. |